Clinic
Ihc Health Services INC
Ihc Health Services INC was paid $25.34M by Medicaid between Jan 2018 and Nov 2024, across 214 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 74% of everything it billed.
33Billing provider infoIHC HEALTH SERVICES INC
LOGAN, UT 84341
LOGAN, UT 84341
33aNPI1831108497assigned 08/05/2006
33bProvider typeEnd-Stage Renal Disease (ESRD) Treatment Clinic/Center
28Total paid$25.34M
24GClaims409,007
24DCodes billed214
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other End-Stage Renal Disease (ESRD) Treatment Clinic/Center providers in Utah
Rank by total paid#1 of 43
Median peer was paid$240K
This provider vs. median106×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SMITH, DENIS controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 65,572 | $3.59M | |
| 2019 | 67,204 | $3.83M | |
| 2020 | 69,814 | $4.18M | |
| 2021 | 93,449 | $6.28M | |
| 2022 | 88,485 | $6.52M | |
| 2023 | 17,690 | $671K | |
| 2024incomplete | 6,793 | $272K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 74% | 41,649 | 19,017 | $18.67M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 26,056 | 21,184 | $690K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 12,992 | 10,419 | $486K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.7% | 12,993 | 11,392 | $440K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.5% | 11,147 | 10,001 | $385K |
| 80050 | General health panel | 1.4% | 3,946 | 3,640 | $363K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.2% | 2,412 | 2,211 | $295K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 7,182 | 6,191 | $237K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 848 | 788 | $178K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,407 | 1,904 | $167K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,776 | 3,465 | $166K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,035 | 1,671 | $158K |
202 more codes
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,003 | $141K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,184 | $130K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,699 | $117K |
| 85027 | <1% | 4,285 | $114K | |
| 80081 | <1% | 1,149 | $110K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,075 | $102K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,064 | $94K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,808 | $91K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,121 | $88K |
| 81001 | <1% | 13,854 | $79K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,008 | $75K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,351 | $69K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 551 | $67K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,885 | $60K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,396 | $58K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,028 | $58K |
| 87186 | <1% | 2,837 | $57K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,843 | $56K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,372 | $55K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,036 | $54K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,045 | $48K |
| 80053 | Comprehensive metabolic panel | <1% | 24,951 | $48K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,760 | $47K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 959 | $45K |
| J2704 | Injection, propofol, 10 mg | <1% | 5,709 | $45K |
| 87081 | <1% | 4,955 | $43K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,162 | $40K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 558 | $40K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 977 | $34K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,123 | $34K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 170 | $29K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,269 | $28K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,778 | $26K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,966 | $25K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 290 | $24K |
| 87660 | <1% | 512 | $24K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,448 | $23K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,499 | $23K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 249 | $22K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 341 | $22K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,139 | $22K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 841 | $21K |
| 87070 | <1% | 1,155 | $21K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,585 | $21K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 781 | $21K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,610 | $19K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,178 | $18K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,683 | $17K |
| 74018 | <1% | 423 | $17K | |
| 80061 | Lipid panel | <1% | 4,029 | $17K |
| 84702 | <1% | 2,901 | $17K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,185 | $17K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 734 | $16K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,598 | $16K |
| 96376 | <1% | 1,992 | $14K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,074 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,161 | $14K |
| 85610 | <1% | 2,874 | $13K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 286 | $13K |
| 82728 | <1% | 1,794 | $13K | |
| 82247 | <1% | 1,940 | $13K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 303 | $12K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,310 | $12K |
| 73610 | <1% | 253 | $11K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,454 | $11K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,395 | $11K |
| 84466 | <1% | 1,449 | $10K | |
| 86850 | <1% | 653 | $10K | |
| 0001A | <1% | 379 | $10K | |
| 73630 | <1% | 245 | $10K | |
| 87077 | <1% | 1,270 | $10K | |
| 84439 | <1% | 2,200 | $10K | |
| 0002A | <1% | 352 | $10K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 51 | $10K |
| 84484 | <1% | 3,691 | $10K | |
| 97161 | <1% | 108 | $9K | |
| 88304 | <1% | 560 | $9K | |
| 87631 | <1% | 120 | $8K | |
| 88307 | <1% | 73 | $7K | |
| 93971 | <1% | 262 | $7K | |
| 84403 | <1% | 281 | $7K | |
| 86364 | <1% | 127 | $6K | |
| 86140 | <1% | 3,502 | $6K | |
| 87480 | <1% | 512 | $6K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 124 | $6K |
| 82607 | <1% | 1,950 | $6K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 800 | $5K |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 166 | $5K |
| 72141 | <1% | 37 | $5K | |
| 82570 | <1% | 1,571 | $5K | |
| 76770 | <1% | 110 | $5K | |
| 86901 | <1% | 772 | $5K | |
| L4386 | Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 41 | $5K |
| 84703 | <1% | 3,116 | $5K | |
| 73562 | <1% | 100 | $5K | |
| 83690 | <1% | 6,512 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,071 | $5K |
| 83880 | <1% | 1,797 | $4K | |
| 80076 | <1% | 707 | $4K | |
| 84132 | <1% | 79 | $4K | |
| J3490 | Unclassified drugs | <1% | 33 | $4K |
| 93017 | <1% | 72 | $4K | |
| 73130 | <1% | 72 | $4K | |
| 76376 | <1% | 657 | $4K | |
| 83735 | <1% | 2,451 | $4K | |
| 84481 | <1% | 266 | $4K | |
| 86003 | <1% | 101 | $3K | |
| 84146 | <1% | 560 | $3K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 644 | $3K |
| 85379 | <1% | 1,966 | $3K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 594 | $3K |
| 83516 | <1% | 518 | $3K | |
| 81025 | <1% | 136 | $3K | |
| 82805 | <1% | 123 | $3K | |
| 76642 | <1% | 127 | $3K | |
| 97162 | <1% | 42 | $3K | |
| 93225 | <1% | 75 | $3K | |
| 85651 | <1% | 2,496 | $2K | |
| 95812 | <1% | 12 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 49 | $2K |
| 82248 | <1% | 728 | $2K | |
| 82950 | <1% | 1,196 | $2K | |
| 0031A | <1% | 115 | $2K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 787 | $2K |
| 87807 | <1% | 57 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 171 | $2K |
| 82784 | <1% | 618 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 144 | $2K |
| 77066 | Tomosynthesis, mammo | <1% | 15 | $2K |
| 84100 | <1% | 803 | $2K | |
| 87088 | <1% | 2,362 | $2K | |
| 82043 | <1% | 888 | $1K | |
| 83540 | <1% | 1,600 | $1K | |
| 87040 | <1% | 1,245 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 254 | $1K |
| 95806 | <1% | 13 | $1K | |
| 86787 | <1% | 1,183 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 590 | $1K |
| 86038 | <1% | 200 | $1K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 582 | $960.48 |
| 82550 | <1% | 190 | $881.68 | |
| 84153 | <1% | 67 | $867.69 | |
| 72100 | <1% | 21 | $811.41 | |
| 83605 | <1% | 2,333 | $775.41 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $773.76 |
| 86803 | <1% | 434 | $670.97 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 83 | $664.44 |
| 12001 | <1% | 29 | $602.60 | |
| L1902 | Ankle orthosis, ankle gauntlet or similar, with or without joints, prefabricated, off-the-shelf | <1% | 15 | $590.83 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 13 | $590.39 |
| G0378 | Hospital observation service, per hour | <1% | 70 | $485.52 |
| 84460 | <1% | 156 | $472.74 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 12 | $443.69 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 15 | $435.08 |
| 81003 | <1% | 120 | $379.93 | |
| 97116 | <1% | 34 | $341.98 | |
| 76801 | <1% | 48 | $317.00 | |
| 86900 | <1% | 416 | $308.80 | |
| 73590 | <1% | 12 | $278.91 | |
| 88302 | <1% | 29 | $264.32 | |
| 83970 | <1% | 16 | $230.12 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 74 | $207.38 |
| 86376 | <1% | 127 | $207.17 | |
| 84478 | <1% | 83 | $206.20 | |
| 85007 | <1% | 325 | $191.20 | |
| 86780 | <1% | 12 | $136.64 | |
| 87340 | <1% | 170 | $131.64 | |
| 85018 | <1% | 30 | $125.64 | |
| 84156 | <1% | 85 | $118.73 | |
| 83525 | <1% | 41 | $114.95 | |
| 82785 | <1% | 13 | $103.06 | |
| 93226 | <1% | 87 | $102.69 | |
| 91300 | <1% | 13 | $85.38 | |
| 85730 | <1% | 260 | $75.18 | |
| 87510 | <1% | 512 | $66.84 | |
| 83001 | <1% | 43 | $64.34 | |
| 84144 | <1% | 13 | $58.79 | |
| 82746 | <1% | 55 | $56.51 | |
| 83615 | <1% | 208 | $52.24 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 291 | $38.58 |
| 87147 | <1% | 26 | $37.67 | |
| 84450 | <1% | 78 | $34.91 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 20 | $32.98 |
| 86800 | <1% | 54 | $28.99 | |
| 90686 | <1% | 33 | $17.13 | |
| 82150 | <1% | 13 | $3.55 | |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 34 | $0.00 |
| 90715 | 0% | 55 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 54 | $0.00 |
| 86480 | 0% | 14 | $0.00 | |
| 43249 | 0% | 18 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 20 | $0.00 |
| 82627 | 0% | 16 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 19 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 28 | $0.00 |
| 84270 | 0% | 30 | $0.00 | |
| 84402 | 0% | 13 | $0.00 | |
| 82670 | 0% | 31 | $0.00 | |
| 96415 | 0% | 27 | $0.00 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 75 | $0.00 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 44 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, DENIS (CFO)
| Provider | Location | Paid |
|---|---|---|
| Ihc Health Services, INC. | Murray, UT | $68.77M |
| Ihc Health Services, INC. | St George, UT | $65.78M |
| Ihc Health Services INC | Ogden, UT | $54.08M |
| Ihc Health Services, INC. | Provo, UT | $44.35M |
| Ihc Health Services, INC. | Cedar City, UT | $20.40M |
| Ihc Health Services, INC. | Salt Lake City, UT | $19.91M |
| Ihc Health Services, INC. | American Fork, UT | $17.19M |
| Ihc Health Services INC | Riverton, UT | $15.31M |
| Ihc Health Services INC | Sandy, UT | $11.66M |
| Ihc Health Services, INC. | Layton, UT | $11.61M |
| Ihc Health Services, INC. | Burley, ID | $5.14M |
| Ihc Health Services INC | Murray, UT | $4.64M |
| Ihc Health Services INC | St George, UT | $4.35M |
| Ihc Health Services INC | Heber City, UT | $4.31M |
| Ihc Health Services, INC. | Orem, UT | $4.18M |
| Ihc Health Services, INC. | Richfield, UT | $3.87M |
| Ihc Health Services INC | Tremonton, UT | $3.55M |
| Ihc Health Services, INC. | Spanish Fork, UT | $3.49M |
| Ihc Health Services INC | Park City, UT | $2.53M |
| Ihc Health Services, INC. | Mt Pleasant, UT | $2.34M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.